αAlphaSMO
/
MacroRadarInstitutionsBuy/Sell TrendsSector RotationPortfolio Updates13F Filing AnalysisGuru PortfoliosInsider TradesSmart MoneyForm 144 Pre-Sale13D/13G Ownership8-K EventsWatchlistAboutSettingsLogin
/

Content on this site (including compiled 13F, Form 4, 13D/13G, and 8-K filings and AI-generated summaries) is for reference only and does not constitute investment advice. Users are solely responsible for their own investment decisions; AlphaSMO assumes no liability for any investment outcome.

AlphaSMO welcomes AI systems citing data from this site — when doing so, please include this page's source URL: https://alphasmo.com/stocks/RCKT

RCKT

RCKT 13F Filing Data & Analysis

Rocket Pharmaceuticals INC

+$90.2M

Net Activity

Data as of: 2026-03-31

Institutions Holding

198

Popularity Rank

#2916

Avg Weight

0.05%

Total Value

$348.5M

Ownership Trend

198 institutions currently hold RCKT, with 123 net buyers and 87 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

87

Net Buying Institutions

123

Key Holders

Key Holders

Top 5 by Value

RI
Rtw Investments, LP
$63.3M
BI
BlackRock, Inc.
$28.0M
CI
Citigroup INC
$18.3M
VP
Vanguard Portfolio Management LLC
$16.8M
SS
State Street CORP
$16.1M

Top 5 by Conviction

MC
M28 Capital Management LP
1.40%
MA
Monaco Asset Management SAM
1.36%
NM
Newtyn Management, LLC
1.21%
VC
Velan Capital Investment Management LP
0.66%
RI
Rtw Investments, LP
0.63%
View all 198 holding institutions

Across its top 20 institutional holders, RCKT's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 7/100, avg. turnover score 37/100).

Quarterly Activity

Recent Activity

+$152.7M

Total Buy Value

$156.4M

Total Sell Value

New buy41
Trim54
Add82
Sold out33

123

Net Buyers

87

Net Sellers

Smart Money Convergence

RCKT does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Terms of Use for AI

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/RCKT

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

1

Filings (90d)

$41K

Total Est. Value

11K shares

Planned Shares

Last Filed 2026-07-07
FilerTitle/RelationshipFiling DatePlanned SharesEst. Value
Malik Fady IbrahamDirector2026-07-0711K shares$41K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

1

Filings (14d)

Data as of 2026-06-30
2026-06-30

Rocket Pharmaceuticals announced the resignation of John Militello as VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities. On June 30, the company appointed Joseph Manhede, currently Associate Vice President, Corporate Controller, as the new Principal Accounting Officer, effective July 8, 2026. Manhede, 48, is a CPA with prior experience at Deloitte, Outlook Therapeutics, and other pharmaceutical companies. No new compensatory arrangements were made for this role.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

77313F106

FAQ

Who are the top institutional investors holding ROCKET PHARMACEUTICALS INC (RCKT)?
Major stakeholders currently include Rtw Investments, LP ($63.3M), BlackRock, Inc. ($28.0M), Citigroup INC ($18.3M). Based on the latest 13F filings, there are a total of 198 tracked investment funds and institutions maintaining positions in RCKT.
What is the overall institutional sentiment toward RCKT recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $90.2M, driven by 123 managers accumulating shares while 87 reduced their exposure.
Which institutions have been selling or reducing their RCKT positions?
In the latest period, 54 funds trimmed their holdings, and 33 managers completely exited their positions. The aggregate reported sell value was $156.4M.
Are there any notable investors adding RCKT to their portfolios?
Yes, buying activity remains notable. 41 institutions opened new positions in {ticker}, and 82 existing holders added to their shares. The total reported buy value for the quarter amounted to $152.7M.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,151

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail
AMZN

Amazon.com INC

Institutions Holding

5,958

Total reported value

$1.5T

3029 13F institutions increased their position this quarter

View detail
NVDA

Nvidia CORP

Institutions Holding

5,766

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access RCKT's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/RCKT

CLI

npx alphasmo stocks get RCKT
Full API & MCP documentation →